


Curriculum Vitae

Abdullah Al-Omari

BSc, MSc, PhD

Personal Profile

Name	Abdullah Ahmad Ali Al-Omari
Gender	Male
Date of Birth	31 th December 1987
Place of Birth	Irbid-Jordan
Nationality	Jordanian
Marital status	Married
Languages	Arabic- Native English- Fluent
Work Address	Scancell Ltd, University of Nottingham Biodiscovery Institute, E floor University of Nottingham, University Park Science Road, Nottingham, NG7 2RD
Mobile	00447947581581
Work E-mail Address	AbdullahAlOmari@scancell.co.uk
E-mail Address	al-omari.abdullah@hotmail.com



Websites

Open Researcher and Contributor Identifier (ORCID): <https://orcid.org/0000-0001-6377-6189>

Researchgate page: [Abdullah Al-Omari \(researchgate.net\)](#)

Google Scholar: [Abdullah Al-Omari - Google Scholar](#)

Current position

- 4th Jan 2021 – Current: Scientist, T cell vaccine group at Scancell Ltd, University of Nottingham Biodiscovery Institute, E floor, University Park Campus, University of Nottingham. www.scancell.co.uk

Biography

Dr Abdullah Al-Omari received his BSc in Nursing from Jordan University of Science and Technology in 2009. He finished his MSc in Cancer Biology from John van Geest Cancer Research Centre (JvGCRC), Nottingham Trent University, UK in 2015. The first MSc project was proposed to identify reliable biomarkers of chronic lymphocytic leukaemia using flow cytometry and bioinformatics approaches. The second MSc project was proposed to identify reliable diagnostics and prognostics biomarkers of colorectal cancer. Dr Al-Omari awarded his PhD in Cancer Immunology from JvGCRC, Nottingham Trent University in 2020. His PhD thesis title was "Identification of distinct markers to differentiate natural and induced T regulatory cells in cancer". In 2020, he also finished his BSc in Biomedical Science from Aston University, Birmingham, UK, as a partial fulfilment of the academic requirements for a degree assessment (equivalency) by the institution of Biomedical science, UK. Dr Al-Omari's research is focus on the development of T cell therapies against cancers including cancer vaccines and T cell bi-specific antibodies. He is also interested in understanding molecular and cellular crosstalk between stromal, tumour, and immune components of solid and hematologic malignancies. Dr Al-Omari is also focused on molecular mediators which create a permissive microenvironment for tumour immune evasion and metastasis progression.

Education and Qualifications

Year	Degree	Institution	Field of study
2005 – 2009	BSc	Jordan University of Science and Technology	Nursing
2013 – 2015	MSc	Nottingham Trent University	Cancer Biology
2015 – 2020	PhD	Nottingham Trent University	Cancer Immunology
2018 – 2020	BSc (Degree Equivalency)	Aston University	Biomedical Science

Professional Memberships

- 2018: British Association for Cancer Research (BACR), membership ID: BAC005168
- 2018: European Association for Cancer Research (EACR), membership ID: EACR26469
- 2018: American Association for Cancer Research (AACR).

Employment History & Work Experience

2016 – 2019: Teaching laboratory demonstrator, Immunology, molecular biology and proteomics labs, School of Science and Technology, Clifton Campus, Nottingham Trent University.

2011 – 2013: Bone marrow transplantation (BMT) practitioner, Oncology Ward, King Abdullah University Hospital, Irbid, Jordan.

2009 – 2010: Oncology practitioner, King Hussein Cancer Centre, Amman, Jordan.

Skills and Research Experience

- 7 years research experience in a highly collaborative, multidisciplinary cancer research centre, working independently as a scientist investigating the immune pathogenesis of cancer.
- 7 years experience in immunological assays, including immune-cell isolation, immune-cell culture, multi-colour flow cytometry, flow cytometry staining (cell-surface, intracellular and nuclear staining), immunological co-culture assays *in vitro* using hanging culture insert, T-cell proliferation and inhibition assays, ELISpot assays, tumour cells killing assays, TCR repertoire analysis, antigen-specific T cell assays, immune-cell profiling, and cell sorting.
- 7 years experience in mammalian cell culture and *in vitro* cellular assays.
- 7 years experience in general molecular biology techniques related to immunotherapy including isolation of DNA and RNA, reverse transcription reaction, polymerase chain reaction (PCR), and gel electrophoresis.
- 7 years experience in proteomics methodologies such as protein isolation, protein quantification, gel electrophoresis, ELISA and western blotting.
- 7 years experience in optimisation murine pre-clinical models for targeted studies.
- 2 years experience in Bioinformatics models such as Artificial Neural Networks (ANN) and Expectation Maximisation (EM).
- 2 years experience in LC-MS/MS mass spectrometry and protein profiling and quantification using SWATH proteomics.
- 2 years experience in developing T cell therapy (peptide-based vaccine) for cancer for clinical use
- Strong experience in statistical data analysis using Graphpad prism software.

- Hand on experience of understanding the public gene expression data bases and survival data such as TCGA, OncoLnc and c-Bio Portal.
- Ability to analyse and interpret experimental data, identifying problem and solving technical issues.
- Ability to develop research work plans and carry out high quality research to meet timelines.
- Ability to work effectively in a team, understanding the strengths and weaknesses of others to help teamwork development.
- Willing to work proactively with colleagues in other work areas/institutions, contributing specialist knowledge to achieve outcomes.
- Communicate new and complex information effectively, both verbally and in writing, engaging the interest and enthusiasm of the target audience.
- Able to present research results at group meetings and conferences.
- Able to write up research results for publication in leading peer-viewed journals.
- Willingness to work outside of regular work hours to achieve goals of projects, including oversight of mouse work as per regulatory guidelines.

Conferences

- 10 – 11 Jun 2014: Beckman Coulter Flow Cytometry Meeting, Burleigh Court, University of Loughborough, UK.
- 9 – 10 Feb 2016: Introduction to the Researcher Development Framework (RDF) Course, Nottingham Trent University, UK.
- 11 – 12 May 2016: School of Science and Technology STAR Conference, Nottingham Trent University, UK.
- 16 Nov 2016: 15th East Midland Proteomics Workshop, Nottingham Trent University, UK.
- 15 – 16 April 2017: ASU-Pharmacy Third Conference: Recent Trends in Postgraduate Research, Jordan.
- 15 Nov 2017: 16th East Midland Proteomics Workshop, Nottingham Trent University, UK.
- 11 – 12 May 2017: School of Science and Technology STAR Conference, Nottingham Trent University, UK.
- 10 – 12 Sep 2018: Response and Resistance in Cancer Therapy, British Association for Cancer Research, University of Kent, UK.

Oral presentations & Posters

- “Molecular mechanisms governing the development of induced T regulatory cells and their significance in the progression of breast cancer”: ASU-Pharmacy Third Conference: Recent Trends in Postgraduate Research, Applied Science Private University, Amman, Jordan, 15 -16 April 2017.
- “Molecular mechanisms governing the development of induced T regulatory cells and their significance in the progression of breast cancer”: STAR Conference, School of Science and Technology, Nottingham Trent University, Nottingham, UK, 11 – 12 May 2017.

Publications

- 1- Al-Omari, A., 2019. Identification of distinct markers to differentiate natural and induced T regulatory cells in cancer (Doctoral dissertation, Nottingham Trent University).
- 2- Cook, K., Xue, W., Atabani, S., Symonds, P., Al Omari, A., Daniels, I., Shah, S., Choudhury, R.H., Weston, D., Metherringham, R. and Brentville, V., 2022. Vaccine Can Induce CD4-Mediated Responses to Homocitrullinated Peptides via Multiple HLA-Types and Confer Anti-Tumor Immunity. *Frontiers in immunology*, 13, p.873947.